Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions

IF 2.1 Q2 Medicine
Liver Research Pub Date : 2026-09-01 Epub Date: 2026-08-26 DOI:10.1016/j.livres.2026.08.001
Quan-Kai Lei, Tong-Xv Wu, Chu-Long Zhang, Yun-Wen Zheng
{"title":"Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions","authors":"Quan-Kai Lei,&nbsp;Tong-Xv Wu,&nbsp;Chu-Long Zhang,&nbsp;Yun-Wen Zheng","doi":"10.1016/j.livres.2026.08.001","DOIUrl":null,"url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) remains challenging to diagnose and manage, particularly at an early stage when curative treatment is most feasible. Artificial intelligence (AI) offers tools for integrating histopathology, radiology, laboratory testing, demographics, and electronic health records, while also creating opportunities for clinician-supervised AI-assisted procedural support. Deep learning applied to digitized pathology slides can support tumor subtype classification, grading, and microvascular invasion assessment. AI-driven imaging methods may support liver and lesion segmentation, small-nodule detection in cirrhotic livers, and non-invasive risk stratification when combined with radiomics and clinical variables. Emerging foundation models, large language models (LLMs), and agentic approaches may help structure evidence, summarize longitudinal records, and support guideline-aligned decision workflows. In AI-assisted treatment-support settings, robotic surgery, endoscopic platforms, and image-guided interventions should be viewed as environments for AI-assisted planning, navigation, documentation, and quality control rather than autonomous treatment systems. Most evidence remains retrospective, single-center, and vulnerable to domain shift. Other limitations include LLM/agentic reliability failures, limited interpretability, privacy constraints, computational burden, incomplete workflow integration, workforce readiness gaps, and uncertain clinical benefit. Future progress will require diverse multimodal datasets, prospective multicenter validation, explainable and lightweight algorithms, standardized data alignment, rigorous governance, patient-centered workflow implementation, staff training, and careful separation of technical feasibility from clinically meaningful outcomes. Responsibly deployed AI may support diagnostic consistency, workflow efficiency, and human–AI collaboration in HCC care.</div></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"10 3","pages":"Pages 189-209"},"PeriodicalIF":2.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542568426000413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) remains challenging to diagnose and manage, particularly at an early stage when curative treatment is most feasible. Artificial intelligence (AI) offers tools for integrating histopathology, radiology, laboratory testing, demographics, and electronic health records, while also creating opportunities for clinician-supervised AI-assisted procedural support. Deep learning applied to digitized pathology slides can support tumor subtype classification, grading, and microvascular invasion assessment. AI-driven imaging methods may support liver and lesion segmentation, small-nodule detection in cirrhotic livers, and non-invasive risk stratification when combined with radiomics and clinical variables. Emerging foundation models, large language models (LLMs), and agentic approaches may help structure evidence, summarize longitudinal records, and support guideline-aligned decision workflows. In AI-assisted treatment-support settings, robotic surgery, endoscopic platforms, and image-guided interventions should be viewed as environments for AI-assisted planning, navigation, documentation, and quality control rather than autonomous treatment systems. Most evidence remains retrospective, single-center, and vulnerable to domain shift. Other limitations include LLM/agentic reliability failures, limited interpretability, privacy constraints, computational burden, incomplete workflow integration, workforce readiness gaps, and uncertain clinical benefit. Future progress will require diverse multimodal datasets, prospective multicenter validation, explainable and lightweight algorithms, standardized data alignment, rigorous governance, patient-centered workflow implementation, staff training, and careful separation of technical feasibility from clinically meaningful outcomes. Responsibly deployed AI may support diagnostic consistency, workflow efficiency, and human–AI collaboration in HCC care.
人工智能在肝癌诊断和人工智能辅助治疗支持中的应用:现状和未来方向
肝细胞癌(HCC)的诊断和治疗仍然具有挑战性,特别是在治疗最可行的早期阶段。人工智能(AI)提供了整合组织病理学、放射学、实验室检测、人口统计学和电子健康记录的工具,同时也为临床医生监督的人工智能辅助程序支持创造了机会。将深度学习应用于数字化病理切片可以支持肿瘤亚型分类、分级和微血管侵袭评估。人工智能驱动的成像方法可以支持肝脏和病变分割、肝硬化小结节检测,以及结合放射组学和临床变量进行无创风险分层。新兴的基础模型、大型语言模型(llm)和代理方法可能有助于构建证据、总结纵向记录和支持与指导方针一致的决策工作流。在人工智能辅助治疗支持环境中,机器人手术、内窥镜平台和图像引导干预应被视为人工智能辅助规划、导航、记录和质量控制的环境,而不是自主治疗系统。大多数证据仍然是回顾性的,单中心的,易受领域转移的影响。其他限制包括LLM/代理可靠性故障、有限的可解释性、隐私约束、计算负担、不完整的工作流集成、劳动力准备差距和不确定的临床效益。未来的进展将需要多样化的多模态数据集、前瞻性的多中心验证、可解释的轻量级算法、标准化的数据对齐、严格的治理、以患者为中心的工作流程实施、员工培训以及谨慎地将技术可行性与临床有意义的结果分离。负责任地部署人工智能可以支持HCC治疗中的诊断一致性、工作流程效率和人-人工智能协作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Liver Research
Liver Research Medicine-Gastroenterology
CiteScore
5.90
自引率
0.00%
发文量
27
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书